Latest news about Ajanta Pharma
Ajanta Pharma Records ₹400 Crore Block Trade on NSE at ₹2968 Per Share
Ajanta Pharma
3,143.40
+68.50(+2.23%)
Company Performance:
View Company Insights1D+2.23%
1M+3.57%
6M+18.42%
1Y+22.01%
5Y+141.55%
More news about Ajanta Pharma
09May 26
Ajanta Pharma Q4 FY26 Results: Revenue Up 21%, PAT Up 18%; FY27 Guidance 16-18%
Ajanta Pharma reported robust Q4 FY26 results with revenue increasing 21% to Rs. 14.22B and net profit rising 18% to Rs. 2.70B. For the full year FY26, revenue grew 17% to Rs. 5,453 cr. The US Generics segment led growth with a 49% annual increase. Management provided FY27 guidance targeting 16-18% revenue growth and an EBITDA margin of 27% (+/- 1%).
06May 26
Jefferies Maintains Buy Rating on Ajanta Pharma with Target Price of ₹3550 on Q4 All-Round Beat
Jefferies has maintained a Buy rating on Ajanta Pharma with a target price of ₹3550, supported by a Q4 all-round beat driven by Africa growth of +37% YoY and US growth of +55% YoY. The brokerage cited improving supply chain normalization and a positive management outlook on branded generics, while noting that US momentum is moderating. India growth remained moderate and Asia saw temporary weakness during the quarter. The positive view is partly offset by a 3% cut to FY27E EPS estimates due to a higher tax rate.
06May 26
Ajanta Pharma Re-appoints Internal, Cost, and Tax Auditors for FY 2026-27
Ajanta Pharma's Board, at its meeting on May 5, 2026, approved the re-appointment of M/s. Aneja Assurance Pvt. Ltd. as Internal Auditors, M/s. RA & Co. (Firm Reg. No. 000242) as Cost Auditors, and M/s. R S Sanghai & Associates (ICAI FRN 109094W) as Tax Auditors for FY 2026-27, with Cost Auditor remuneration subject to member ratification under Section 148 of the Companies Act, 2013.
06May 26
Ajanta Pharma Grants 1,45,000 Stock Options, Cancels 850 ESOPs Under Share Based Incentive Plan 2019
Ajanta Pharma's Nomination and Remuneration Committee, at its meeting on May 5, 2026, granted 1,45,000 stock options under the Ajanta Pharma Share Based Incentive Plan 2019, with each option covering one share and an exercise period of three months from the date of vesting. The committee also approved the cancellation of 850 stock options, which have been credited back to the ESOP pool. The disclosures were made to BSE Limited and the National Stock Exchange of India under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
22Apr 26
Ajanta Pharma US FDA Inspection at Paithan Facility Concludes with Form-483 Issuance
Ajanta Pharma Limited disclosed that US FDA inspection at its Paithan manufacturing facility concluded with Form-483 issuance containing 5 observations. The inspection ran from April 13-21, 2026, and the company will respond within the required timeline.
06Apr 26
Ajanta Pharma Submits Q4FY26 Compliance Certificate Under SEBI Depositories Regulations
Ajanta Pharma Limited filed its compliance certificate under SEBI (Depositories and Participants) Regulations, 2018 for Q4FY26 on 6th April 2026. The certificate, issued by registrar MUFG Intime India Private Limited, confirms proper handling of securities dematerialisation processes during the quarter ended 31st March 2026, demonstrating the company's adherence to regulatory requirements.
04Apr 26
Ajanta Pharma Promoter Aayush Agrawal Pledges 3.85 Lakh Shares for Loan Enhancement
Aayush Agrawal, promoter of Ajanta Pharma Limited, has pledged 3,85,000 shares (0.31% of total capital) on March 30, 2026, to increase loan facilities. The disclosure was made to stock exchanges on March 31, 2026, under SEBI regulations. Aayush Agrawal Trust holds 1,41,12,924 shares (11.30%) in the company, with the new pledge adding to existing encumbrances.
01Apr 26
Ajanta Pharma Confirms Non-Applicability as Large Corporate Entity Under SEBI Framework
Ajanta Pharma Limited has confirmed to stock exchanges that it does not qualify as a Large Corporate Entity under SEBI's debt securities framework. The company reported nil outstanding borrowings as of March 31, 2026, and maintains a CARE A1+ credit rating, demonstrating strong financial position and regulatory compliance.
01Apr 26
Ajanta Pharma Promoter Ravi Agrawal Pledges 9.35 Lakh Shares for Refinancing
Ajanta Pharma promoter Ravi Agrawal has disclosed pledge transactions on 9,35,000 equity shares for refinancing purposes. The transactions involved multiple financial institutions between March 25-27, 2026, with net pledged shareholding remaining at 4.85% of total share capital. The disclosure was made under SEBI regulations to stock exchanges where the company is listed.
28Mar 26
Ajanta Pharma Promoter Aayush Agrawal Creates and Releases Pledge on Shares
Ajanta Pharma promoter Aayush Agrawal has disclosed pledge activities involving creation of 10.43 lakh shares and release of 8.50 lakh shares under SEBI regulations. The transactions were conducted with multiple lenders including Motilal Oswal Financial Services and Ashika Credit Capital, with post-event encumbered holdings of 83.97 lakh shares representing 6.72% of total share capital.
06Mar 26
Ajanta Pharma Promoter Aayush Agrawal Discloses Share Pledge Transactions Under SEBI Regulations
Aayush Agrawal, promoter of Ajanta Pharma Limited, disclosed share pledge transactions under SEBI regulations on 6th March, 2026. The disclosure covers creation of pledge on 7,87,933 shares for additional loans and release of pledge on 8,32,178 shares for loan repayment and margin reduction. Multiple transactions were conducted with various financial institutions including Aditya Birla Capital Ltd, Deutsche Bank A.G, and Bajaj Finance Ltd between February and March 2026. Post-transactions, 82,04,162 shares representing 6.57% of total share capital remain pledged.
23Feb 26
Ajanta Pharma Promoter Aayush Agrawal Creates & Releases Pledge on 2 Lakh Shares
Ajanta Pharma promoter Aayush Agrawal disclosed simultaneous pledge release and creation transactions involving 2,00,000 shares each with Aditya Birla Capital Ltd for loan repayment and increase purposes. Despite these transactions occurring on February 17 and 19, 2026, his total encumbered shareholding remains at 82,48,407 shares representing 6.60% of the company's share capital.
10Feb 26
Ajanta Pharma Clarifies No Involvement in Restaurant Brands Asia Acquisition Deal
Ajanta Pharma Limited has clarified to stock exchanges that it is not involved in the acquisition of Restaurant Brands Asia, contrary to media reports. The company stated that while Lenexis Foodworks Pvt. Ltd., managed by a section of its promoter group, is independently pursuing the acquisition, Ajanta Pharma and its management have no involvement in the transaction. The clarification was submitted under SEBI regulations on February 10, 2026.
30Jan 26
Ajanta Pharma Vests 4,300 Stock Appreciation Rights and Cancels 800 Employee Stock Options
Ajanta Pharma Limited's Nomination and Remuneration Committee approved the vesting of 4,300 cash-settled Stock Appreciation Rights on 30 January 2026, originally granted on 30 January 2025. These SARs will be settled in cash based on the company's share price on 2 February 2026, with no equity dilution as no new shares will be issued. Additionally, the committee cancelled 800 employee stock options due to grantees leaving the company before vesting, with these options returned to the ESOP pool for future allocation.
30Jan 26
Ajanta Pharma Reports 16% Growth in Q3 Consolidated Net Profit to ₹2.7 Billion
Ajanta Pharma delivered strong Q3 financial results with consolidated net profit of ₹2.7 billion, representing a 16% year-on-year increase from ₹2.33 billion in the corresponding quarter last year. The growth demonstrates the pharmaceutical company's robust operational performance and effective business management strategies during the quarter.
20Jan 26
Ajanta Pharma Clarifies No Interest in Restaurant Brands Asia Acquisition
Ajanta Pharma has officially denied any interest in acquiring shares of Restaurant Brands Asia, according to Reuters reports. The pharmaceutical company's clarification addresses market speculation and provides clarity about its investment strategy, confirming it has not explored purchasing shares in the restaurant chain operator.
13Jan 26
Ajanta Pharma Establishes Wholly Owned Subsidiary in Ireland for Pharmaceutical Operations
Ajanta Pharma Limited has established a wholly owned subsidiary, 'Ajanta Pharma Ireland Ltd.,' incorporated in Ireland to conduct pharmaceutical business operations. The formation was disclosed on January 13, 2026, under SEBI Regulation 30, representing the company's strategic expansion into the Irish pharmaceutical market. As a newly incorporated entity, the subsidiary aligns with the parent company's core pharmaceutical operations and strengthens its international presence.
13Jan 26
Ajanta Pharma Establishes New Subsidiary in Ireland
Ajanta Pharma has created a new subsidiary in Ireland named Ajanta Pharma Ireland, representing a strategic expansion into the European market. This move strengthens the company's international presence and could enhance its access to European pharmaceutical markets through improved operational structure.
12Jan 26
Ajanta Pharma schedules Q3FY26 earnings conference call for January 30, 2026
Ajanta Pharma announced an earnings conference call for January 30, 2026 at 16:30 hrs IST to discuss Q3FY26 unaudited financial results. The company filed this under SEBI Regulation 30 on January 12, 2026. Multiple dial-in options include international toll-free numbers for USA, UK, Hong Kong, and Singapore, with Diamond pass registration for faster access. Call playback will be available on the company website within 120 minutes.
31Dec 25
Ajanta Pharma Promoter Aayush Agrawal Creates Multiple Fresh Pledges
Ajanta Pharma promoter Aayush Agrawal Trust has created multiple fresh pledges in December 2025, including the latest disclosure of 1,27,660 shares for loan increase and an earlier pledge of 16,02,500 shares for bank guarantee purposes, continuing the pattern of active promoter financing activities.
30Dec 25
Motilal Oswal Maintains 'Buy' Rating on Ajanta Pharma with Target Price ₹3,145
Motilal Oswal has reaffirmed its 'Buy' rating on Ajanta Pharma with a specific target price of ₹3,145, emphasizing the company's strategic initiatives across key markets in India, Asia, and Africa. The brokerage firm expects the pharmaceutical company to sustain robust industry outperformance through its focused approach in branded generics markets.
24Dec 25
Ajanta Pharma Signs In-licensing Agreement With Biocon For Semaglutide Supply
Ajanta Pharma has entered into a strategic in-licensing agreement with Biocon Limited for Semaglutide supply across 26 countries, securing exclusive marketing rights in 23 markets and semi-exclusive rights in 3 markets. The GLP-1 receptor agonist is expected to launch in late 2026 or early 2027, leveraging Ajanta Pharma's strong presence across Africa, Middle East and Central Asia regions.
10Dec 25
Ajanta Pharma Promoters Release Pledge on 4.2 Lakh Shares
Ajanta Pharma has reported pledge releases by two promoters - Ravi Agrawal releasing 10,50,000 shares due to excess pledge and Aayush Agrawal releasing 4,20,255 shares citing upward movement in market price. The disclosures were made to BSE and NSE under SEBI regulations, demonstrating the company's commitment to transparency and regulatory compliance.
03Nov 25
Ajanta Pharma Sets November 10 as Record Date for First Interim Dividend
Ajanta Pharma has declared a first interim dividend of Rs. 28 per share for FY 2026, with a record date of November 10, 2025. The total dividend payout amounts to Rs. 349.82 crore. This announcement follows strong Q2 FY 2026 results, with revenue up 14% to Rs. 1,354 crore and PAT growing 20% to Rs. 260 crore. The company reported growth across all segments, with US Generics showing a significant 48% increase. Ajanta's performance in key therapeutic areas outpaced the Indian Pharmaceutical Market growth.
03Nov 25
Ajanta Pharma Reports 20% Profit Growth in Q2 FY 2026, Declares Rs. 28 Interim Dividend
Ajanta Pharma Limited announced robust Q2 FY 2026 results, with revenue from operations increasing 14% to Rs. 1,354.00 cr. Profit After Tax (PAT) grew 20% to Rs. 260.00 cr. The US Generics segment showed remarkable 48% growth. The company's branded generics business, accounting for 72% of total revenue, grew by 8%. Ajanta outperformed the Indian Pharmaceutical Market in key therapeutic areas. The Board approved a first interim dividend of Rs. 28 per share. The company maintains a strong product pipeline with 50 commercialized ANDAs and 22 awaiting US FDA approval.
24Oct 25
Ajanta Pharma Board to Consider First Interim Dividend for FY 2025-26
Ajanta Pharma's Board of Directors will meet on November 3, 2025, to consider declaring the first interim dividend for FY 2025-26. They will also review unaudited financial results for Q2 and H1 FY 2025-26. If a dividend is declared, November 10, 2025, may be set as the record date for shareholder eligibility. The meeting aligns with regulatory requirements and will provide insights into the company's financial health and shareholder return policies.
10Sept 25
Ajanta Pharma Promoter Releases Pledge on 130,000 Shares for Refinancing
Ravi Agrawal, a key promoter of Ajanta Pharma Limited, has released a pledge on 130,000 shares for refinancing purposes. The company has filed the necessary regulatory disclosures with both BSE and NSE in compliance with SEBI regulations. This action may be viewed positively by the market as it could indicate the promoter's confidence in the company's financial stability.
19Aug 25
IT Department Raids Ajanta Pharma Premises
The Income Tax Department has conducted raids at Ajanta Pharma's premises. While the raid has been confirmed, specific details about its scope, duration, or reasons remain undisclosed. This development has raised concerns in the pharmaceutical sector, potentially affecting Ajanta Pharma's operations, reputation, and market standing. Stakeholders are awaiting further information about the nature of the investigation and its possible impact on the company's business operations.
28Jul 25
Ajanta Pharma Reports Robust Q1 Results with 14% Revenue Growth
Ajanta Pharma announced robust Q1 financial results, with consolidated revenue increasing 14% to ₹1,303.00 crore. Net profit rose 4% to ₹255.00 crore, while EBITDA grew 6% to ₹351.00 crore. The branded generics segment, accounting for 73% of total revenue, grew by 9% to ₹941.00 crore. US generics showed exceptional growth of 36%, reaching ₹310.00 crore. The company launched 8 new products in India and 12 in emerging markets during the quarter.
14Jul 25
Ajanta Pharma: Significant Block Trade of 3.16 Lakh Shares on NSE
A significant block trade of approximately 3.16 lakh (315,631) shares of Ajanta Pharma was executed on the National Stock Exchange (NSE). The transaction occurred at Rs. 2,619.50 per share, totaling Rs. 82.68 crore. This large-scale trade indicates substantial market interest in the pharmaceutical company's stock, potentially impacting its short-term price and trading volumes.
02May 25
Ajanta Pharma Q4 FY25: Revenue Grows, Margins Shrink Amid Market Challenges
Ajanta Pharma's Q4 FY25 results show 11% YoY revenue growth to Rs 11.70 billion and 11.10% PAT increase to Rs 2.30 billion. EBITDA grew 6.80% YoY to Rs 2.97 billion, but margins contracted. Systematix maintains 'Buy' rating with revised target price. Results published in Business Standard and Navakal on May 1, 2025.
30Apr 25
Ajanta Pharma Reports 11% Growth in Q4 Profit and Revenue, Margin Contracts
Ajanta Pharma Limited announced strong Q4 FY2025 results with revenue up 11% to ₹1,170.00 crore and net profit increasing 12.50% to ₹225.00 crore. EBITDA grew 6.83% to ₹297.00 crore, though the EBITDA margin slightly decreased. The company distributed ₹700.00 crore to shareholders in FY2025, representing 76% of PAT. An earnings conference call is scheduled for April 30, 2025, to discuss the results further.
21Mar 25
Ajanta Pharma Joins FTSE All World Index, Expands Manufacturing Capacity
Ajanta Pharma has been added to the FTSE All World Index, potentially attracting $23.80 million in foreign investment. The company also announced plans to triple its liquid formulation production capacity from 6 million to 18 million bottles annually at its Pithampur site. This Rs. 92 crore expansion project, funded through internal accruals, is expected to be completed by Q1 FY 2026.
20Mar 25
Ajanta Pharma to Invest ₹92 Crore in Pithampur Facility Expansion
Ajanta Pharma Limited plans to invest ₹92 crore to expand its Pithampur manufacturing site, adding a new liquid formulation facility. The expansion will increase production capacity from 6 million to 18 million bottles per annum on a single shift basis. The project, financed through internal accruals, is set to be completed by Q1 FY 2026. This strategic move aims to meet growing global demand and alleviate current production pressures, with the existing facility operating at 175% utilization.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,794.20
(+0.44%)
6,655.50
(+0.26%)
4,572.20
(+2.43%)
1,383.30
(+0.46%)
1,105.90
(+0.69%)
1,276.00
(+0.34%)
2,273.30
(+1.16%)
2,372.70
(-0.15%)
1,464.10
(+0.72%)
1,390.80
(+0.37%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
